T his study was performed to meet the requirements for a regulatory submission of a ''first in man'' clinical trial, testing an investigational new drug (IND) for the treatment of achromatopsia (ACHM). ACHM is a hereditary retinal disorder with an estimated prevalence of 1:30,000 1 for which currently no treatment exists. The prevalence is greater in certain genetically isolated areas like the Micronesian atoll Pingelap, where up to 6% of the population are affected by the condition. 2 ACHM is a congenital disease that exclusively impairs cone function. Affected individuals suffer pronounced photopic defects such as total color blindness, reduced visual acuity, hemeralopia (day blindness), nystagmus, and photophobia. 3 To date, six genes have been identified that link to ACHM. Five of them constitute essential parts of the cone phototransduction cascade as they encode either for cyclic nucleotide-gated channels (CNGA3 4 /CNGB3 5 ), phosphodiesterases (PDE6C 6 /PDE6H 7 ), or a related G protein (GNAT2 8 ). The sixth gene is AFT6. It encodes a protein that is part of the unfolded protein response in the endoplasmic reticulum. 9 At the University Eye Hospital Tübingen, we performed the first clinical gene therapy for ACHM caused by mutations in CNGA3 using subretinal administration of rAAV8.hCNGA3 (NCT02610582) in 2015. Here, we describe findings from the preclinical biodistribution study, which evaluated safety aspects including the extent of biodistribution within the visual system, the extraocular tissues (e.g., germ line), and shedding of any genetically modified organism (GMO) into the environment after subretinal versus intravitreal injections. Cynomolgus monkeys were chosen because their ocular anatomy is rather humanlike (i.e., presence of a macula) and suited to mimic surgical procedures used in patients. These data are expected to be relevant to all ocular gene therapies utilizing the adenoassociated virus serotype 8 (AAV8) capsid and possibly other serotypes with similar tropism, as the affinity of capsid surface epitopes toward local receptors helps to define their distribution pattern. Recent evidence of innate and adaptive immunity toward AAV epitopes increases the significance of these findings. 10, 11 
MATERIALS AND METHODS
Cynomolgus monkeys (nonhuman primates, NHP) were treated and cared for at the Covance Preclinical Services GmbH test facility in Muenster, Germany. The study was conducted with great care to ensure the well-being of the animals and was approved by the local authorities (Regierungspraesidium of North-Rhine Westphalia). All animal procedures were performed in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research, and in full compliance with the guidelines of the European Community (EUVD 86/609/EEC) for the care and use of laboratory animals, as well as in accordance with Good Laboratory Practice (GLP) standards as defined by German GLP monitoring authorities and in compliance with U.S. Food and Drug Administration and Good Laboratory Practice regulations.
Animals
A total of 22 NHP were assigned to four study cohorts. Six animals (three of each sex) were assigned to cohorts 1 to 3 and treated with subretinal injections (SR). Cohort 1 received vehicle only: balanced salt solution, BSS (Alcon Laboratories [UK] Ltd., Camberley, UK) with 0.001% PF-68 surfactant (BASF, Ludwigshafen, Germany). Cohorts 2 and 3 received single SR of either 1 3 10 11 vector genomes (vg) (low dose) or 1 3 10 12 vg (high dose), respectively. Cohort 4 consisted of four animals (two of each sex) and received single intravitreal injections (IVT) of 1 3 10 12 vg (high dose) to mimic leakage from the subretinal space (e.g., through retinotomy or macular hole) or via falsa injection.
Production of Recombinant AAV8
Recombinant AAV8 carrying a transgene cassette based on an AAV2 genome (pseudotype AAV2/8) was manufactured according to good manufacturing practice (GMP) guidelines. It contained a cone-arrestin 3 promoter driving CNGA3 expression that has been shown to have therapeutic effect in the Cnga3 À/À mouse model. 12 GMP grade cis and trans plasmid DNA was provided by Aldevron (Fargo, ND, USA) using a highquality characterized Escherichia coli master cell bank (MCB), and Atlantic BioGMP (Nantes, France) produced the GMP grade viral particles (rAAV.hCNGA3) utilizing a transient double-transfection protocol of an HEK293 MCB fully characterized according to the European Pharmacopeia. Harvested cells were lysed and supernatant PEG-precipitated, treated with benzonase, and purified by two rounds of caesium chloride gradient ultracentrifugation followed by a tangential flow filtration step for diafiltration and concentration. After formulation, the resulting drug substance was stored at À708C until application.
Surgery and Postsurgical Care
Animals received general volatile anesthesia with isoflurane; (peri-)orbital regions were treated with 10% povidine iodine solution and sterile surgical drapes applied as in the clinical setting. A temporal canthotomy was performed for improved access, and three transconjunctival sclerotomies were made after transillumination confirmed the location of pars plana. 
DNA Extraction and qPCR
DNA was extracted from all tissue and blood samples prior to qPCR using QIAsymphony DSP DNA Mini kit with Qiagen Reagent DX, and the QIAsymphony DSP DNA Mini kit, respectively (Qiagen, Hilden, North Rhine-Westphalia, Germany). DNA concentrations were measured using spectrophotometry. Eight cryosections (20 lm thick) from whole eye cups were processed for each animal and pooled into one sample for extraction. Also, for heart, lung, and liver, three samples were extracted separately and the eluates pooled to result in one sample analyzed by qPCR. For all tissue samples and blood, 1 lg DNA was used per qPCR reaction. QIAsymphony DSP Virus/ Pathogen kit for biofluids was used for the remaining samples. DNA concentration of these samples was not determined, due to the inclusion of carrier RNA in the extraction procedure. Here, samples of 5 lL were analyzed neat by qPCR. For presentation, results are normalized to 1 mL source material to improve interpretability. To validate the qPCR assay, a positive control (transgene plasmid) was serially diluted from 5 3 10 7 to 50 copies/reaction. The data generated from this dilution series were used to construct a standard curve for quantitative data analysis. Samples that tested positive after 40 cycles of amplification, but below 50 copies, were supposed to contain a nonquantifiable number of genomes per reaction (between 1 and 50), and thus deemed ''<LLOQ.'' Samples without amplification after 40 cycles were deemed ''negative.'' This validated qPCR assay was used to analyze each sample in triplicate, with one of the replicates spiked with a known quantity of the qPCR positive control to assess for the presence of any potential inhibitors in the sample.
RESULTS

Animal Dosing
All randomly assigned animals successfully underwent dosing per protocol within 3 consecutive days. Complete subretinal placement was evident in direct visualization through the operating microscope and involved the targeted macular area in all animals. All biofluid and tissue sampling could be performed according to standard operating procedures and in strict accordance with GLP guidelines.
Animals Injected With Vehicle Only
All tissue and biofluid samples taken from animals in the control cohort injected with vehicle tested negative for presence of transgenic DNA, with exception of one tear sample and two nasal swabs taken from one female animal. In these samples, transgenic DNA quantities detected were all below the lower level of quantification (LLOQ ¼ 50 copies per reaction). All consecutive tear samples and nasal swabs from this animal tested negative, as did all other biofluid and/or tissues samples at all time points.
Animals Injected With Vector Solution
Shedding occurred to some degree in all animals injected with vector solution and in all types of biofluids tested. An overview of maximal amount of detected vector genomes/mL biofluid and duration of shedding by route of administration and dose is given in Table 1 . Of the biofluids that shed into the environment (tears, nasal secretions, and urine) no sample tested above the LLOQ later than day 7. Maximal shedding in most animals was observed 2 days after injection. After SR, shedding was most pronounced in tear fluid, followed by nasal secretions and urine. After IVT, the largest amount of vector was also shed via tears, but was followed by urine and lastly nasal secretions. Table 1 presents time points when shedding of all samples of a cohort were below LLOQ (residual shedding), or below level of detection (no shedding). Figure  1 summarizes the qualitative changes of shedding status (positive, residual, or negative) per cohort and biofluid over the observed time frame. To characterize time dependency it introduces T 1/2 as a semiquantitative ''shedding status halflife'': the point in time (in days) after administration on which ‡50% of a cohort's samples test below LLOQ. Individual shedding results of all animals are shown in Figures 2 to 4 , plotted in log scale against time of harvest, capturing both the variability between animals of the same cohort and differences between cohorts.
Individual Lacrimal Shedding Results
Shedding via tear film was subject to a pronounced dose effect (Figs. 1, 2; Table 1 ). In animals from the low-dose group, fewer copies were found in positive samples, and tears were negative after a shorter time, compared to the high-dose group. Subretinal application of the high dose led to a 33-fold increase in maximal shedding (cohort mean) compared to the low dose, and shedding persisted at quantifiable levels for at least 1 week after surgery. Route of administration also had distinct effects on shedding via tears. While fewer copies were detected following intravitreal compared to SR (with the same amount of vector applied), both groups featured quantifiable samples after 1 week. Where only four out of six animals from the lowdose group shed vector via tears at any given time point, all (6/ 6) animals from the high-dose subretinal and (4/4) intravitreal cohorts shed vector via tears over the course of the study. Individual results are displayed in Figure 2 and copy numbers/ mL are given in Supplementary Material S1.
Individual Shedding Results via Nasal Secretions
Shedding via nasal secretions was less dependent on dosage than shedding through tears and urine (Figs. 1, 3 ; Table 1 ). Shedding in the low-dose subretinal cohort receded more quickly (T 1/2 after 4 vs. 7 days for high dose) and was slightly less prevalent (5/6 animals), compared to the high-dose cohort (6/6). In line with the slightly increased prevalence after highdose injection, dose escalation by one log unit also entailed a modest 1.4-fold increase in maximal copy numbers (cohort 
Tears and urine featured a response to both dose and route of administration. While dose escalation led to increased copy numbers and shedding duration, route of administration mostly affected copy numbers, rather than shedding duration, which was generally similar between subretinal and intravitreal injections. Blood samples did not show any vector presence after low-dose subretinal injections, and limited vector load after high-dose subretinal injections, while intravitreal administration led to immediate, strong, and persistent presence of vector in blood. First column: Groups. Second column: Time point of maximal shedding, vector genomes/mL of raw sample (cohort mean). Third column: Persistence of vector shedding, characterized by two thresholds: residual shedding ¼ all samples testing at least below LLOQ, no shedding (none) ¼ all samples negative. FIGURE 1. Shedding prevalence per cohort and biofluid during the observed time frame. Switching between columns compares results of the same sample type (i.e., shedding via tear) over different cohorts (i.e., subretinal low versus high dose), while switching between rows compares different sample types in the same cohort. The most notable difference is visible in the bottom row of the graph, displaying vector presence in blood across the three cohorts. y-axes: sample status in % of animals in the given cohort, color-coded. x-axes: days after injection. T 1/2 : ‡50% of the cohort's samples test below LLOQ or negative. Individual sample status is color-coded. mean). Like dose escalation, route of delivery had only a minor effect on shedding via nasal secretions. Between subretinal and intravitreal cohorts of the same dose, there was an equal prevalence (all animals in both groups) and duration of shedding, with 50% of animals in both cohorts featuring quantifiable qPCR results 7 days after surgery. A slight difference between the high-dose groups was found in a 1.7-fold elevation of copy numbers after SR, relative to intravitreal administration. Individual results are displayed in Figure 3 and copy numbers/mL are given in Supplementary Material S1.
Individual Shedding Results via Urine
Shedding via urine was strongly dose dependent ( Figs. 1, 4 ; Table 1 ). Foremost, it was barely detectable and nonpersistent in the low-dose cohort. Due to the low-dose cohort's low baseline, dose escalation by one log unit led to an 18.5-fold increase in maximal shedding (cohort mean) compared highdose SR.
In contrast to the clear dose dependency, route of administration had subtler effects. Shedding prevalence was similar between IVT (4/4) and SR (5/6). Between these highdose groups, copy numbers were moderately increased (2.7-fold) in subretinally injected animals, while shedding above LLOQ lasted 2 days longer after IVT. Individual results are displayed in Figure 4 and copy numbers/mL are given in Supplementary Material S1.
Transduction of the Visual System
At necropsy (91 days post injection), tissues of the visual pathway ( Fig. 5 ; Table 2 ) were collected for formal biodistribution analyses. The segments of the visual system were sampled individually along the pathway taken by light (anterior segment, retina, optic nerve and chiasm, lateral geniculate nucleus [ LGN], and visual cortex). Presence of vector in the aqueous humor was exclusively dependent on route of administration, while upstream distribution along the visual pathway was strongly associated with both dose and route of administration.
Ninety-one days after surgery, only one aqueous humor sample across both subretinal cohorts exhibited vector presence, while all samples in the intravitreal cohort were clearly above LLOQ. This was reversed within the eye, where compared to IVT, subretinal application of the same dose Of note, the high-dose subretinal cohort mean on day 3 was skewed by a single animal. It tested with 4.6 3 10 Eþ7 vg/mL on day 3, 53 times more than it tested on day 2, and 33 times more than it tested on day 4. The measurement was not omitted, although such variation was not seen in any other instance across the study. LLOQ ¼ lower limit of quantification (50 copies/reaction). resulted in 53 times higher copy numbers in whole retinal sections. A 10-fold dose escalation in SR caused a 37-fold increase of copy numbers detected in retinal tissue. The respective presence of vector in the retina carried over to following stations along the visual pathway. In optic nerve samples, dose escalation led to a 20-fold increase in copy numbers, while compared to IVT, SR resulted in 2.9-fold increased copy numbers. In line with the difference in copy numbers, five of six animals demonstrated vector presence in optic nerve samples after subretinal high-dose injections, as opposed to two of six animals in the low-dose cohort. A similar pattern, although with markedly lower copy numbers, also carried over to the optic chiasm, LGN, and visual cortex. Only one sample in the study (high-dose SR cohort) tested above the LLOQ at the level of the LGN, while not a single sample from the visual cortex tested positive for vector DNA. Table 2 shows copy numbers detected in each segment. Figure 5 illustrates the distribution of vector along the visual pathway in each cohort.
Biodistribution Outside the Visual System
The study also analyzed samples from blood ( Figs. 1, 6 ; Table  1 ), major organs, and draining lymphatic tissue. Biodistribution in the systemic circulation and lymphatic tissues was strikingly dependent on the route of administration, but barely dose dependent. For example, while dosage had a moderate effect on biodistribution via blood, injecting intravitreally resulted in a 464-fold increased blood vector load compared to SR of the same dose, and vector presence in blood persisted in all animals of the IVT cohort until 91 days. Individual results are displayed in Figure 6 and copy numbers/mL are given in Supplementary Material S1.
Large Organs and Lymphatic Tissue
In line with elevated vector load in blood after IVT, draining lymph node and spleen contained significant amounts of vector genomes in animals of the IVT cohort, but virtually no copies after subretinal delivery (Figs. 7, 8 ). Relative amounts of vector genomes found in the lymph nodes (Table 3) after IVT were increased around 430-fold for deep cervical, 1000-fold for On day 91, relevant copy numbers were detected only in the aqueous humor of IVT animals. Vector deposition in the retina and upstream the visual pathway was most pronounced in high-dose SR animals. retropharyngeal, 510-fold for mandibular, and 490-fold for mesenteric lymph nodes, compared to SR. IVT led to an approximately 7400-fold increase in copy numbers in spleen compared to SR. Liver samples were also positive in the intravitreal cohort, while heart, tongue, spinal cord, adrenal glands, and, importantly, the gonads were free of vector genomes in all animals of all cohorts (Table 4 ).
Summary
The study was designed to explore the shedding and biodistribution characteristics after subretinal delivery of AAV8 when mimicking the clinical scenario in patients. The IVT control group was added to test effects of inadvertent primary injection into the vitreous (via falsa) and/or a secondary delivery into the vitreous cavity through a retinal tear (e.g., macular hole formation) in the context of subretinal delivery. Both dose and route of delivery change the distribution profile, and Figure 9 shows a proposed model based on the major finding that intravitreal placement of AAV8 results in much higher viremia and contact with immunecompetent cells. It highlights the potential of immunecompetent effector cells to influence local reactions to the viral vector in the eye.
DISCUSSION
To the best of our knowledge, this study reports the most comprehensive data on viral shedding and biodistribution of recombinant adeno-associated virus serotype 8 (rAAV8) after subretinal versus intravitreal injection (IVT) in nonhuman primates. This study was conducted in strict adherence to GLP guidelines and designed to generate data on biodistribution/shedding after subretinal and IVT in a protocol mimicking clinical application of rAAV8 gene therapy as closely as possible. In contrast to the protocol of the clinical trial, sclerotomies were not sutured in primates with the aim to reduce postsurgical irritation. However, this did not prevent digital manipulation of the treated eyes by the animals once transferred back to the cages. This may have affected biodistribution/shedding outcomes, and any such manipulation can easily be avoided in the clinical setting.
One important component of patient safety is avoidance of germ line transduction. 13, 14 There was no vector presence in the germ line, regardless of sex, vector dosage, or route of administration. Shedding of GMO into the environment is another important aspect, and our data show that shedding to the environment receded below LLOQ by 1 week after surgery, with 21% of samples without detectable vector At a similar dose, intravitreal delivery (bottom row) was associated with pronounced deposition in lymph nodes close to and far from the eye, compared to subretinal delivery. Assumed organ weight: 0.1 g per lymph node. genomes and 79% of all samples testing below LLOQ. In line with other reports, vector biodistribution and consequent deposition in internal organs were minimal in the subretinal cohorts. 15 Both dose (1Eþ11 vs. 1Eþ12) and delivery (subretinal versus intravitreal) had an impact on biodistribution and shedding. Reducing the dose by one log unit resulted in 30% to 97% fewer copies off-target and shorter duration of shedding. Retinal gene transfer to the retina after IVT was at least one order of magnitude less compared to SR of the same vector dose. Vector genomes detected on day 1 in the intravitreal cohort's bloodstream accounted for 0.26% of the total dose applied, in contrast to 0.0006% after subretinal delivery of the same dose. This is in line with IVT leading to increased shedding into the systemic circulation via the anterior chamber. The observation that mesenteric lymph nodes, which do not drain from the injection site, did show a similar degree of vector deposition as deep cervical, retropharyngeal, and mandibular lymph nodes, also supports the notion of circulation-mediated biodistribution after IVT. Taken together, this evidence suggests a biodistribution profile not unlike what is described for intramuscular and intravenous injections. 16, 17 Such a systemic visibility after IVT may promote vector recognition by the immune system and might help to explain any form of immune response after gene therapy. 11, 18, 19 Recent findings complement this hypothesis by showing a qualitative difference in immune response after IVT. 10 It is important to note, however, that the absolute risk of any clinically relevant systemic toxicity in a patient after a retinal tear during subretinal delivery or IVT delivery can still be managed effectively. This is evident from clinical trials, where much higher dosages of rAAV8 were delivered primarily into the systemic circulation without causing serious adverse events. 20 However, these trials have shown that systemic exposure to significant numbers of any rAAV serotype can induce humoral and cellular immune response followed by directed removal of successfully transduced target cells by cytotoxic T lymphocytes. 21 Previous studies in large animal models have demonstrated that rAAV8 gene therapy has a favorable safety profle 22 and efficiently transduces photoreceptors, 23, 24 and that vector genome can be found along the visual pathway after subretinal delivery of rAAV. 25, 26 Our data are in line with these reports and show that dose and route of application are important determinants of the extent of this distribution pattern. 27 While our data do not explain the mechanism of transduction along the visual pathway, they clearly show that both routes of application can lead to anterograde vector genome distribution along the axons of the ganglion cells up to the LGN. Intriguingly, this would indicate that subretinal rAAV8 does transduce ganglion cells. Alternative explanations would involve trans-synaptic mobility and/or vector solution traveling in the subretinal space to reach the optic nerve sheath and access to the cortex, for example, via cerebrospinal fluid. Both seem rather unlikely scenarios and are not supported by the fact that the visual cortex is free from vector genomes.
When taking all biodistribution and shedding data into consideration, we argue that SR offers the more favorable set of results. With constant improvements of subretinal surgery, 28, 29 and the predominant intention of treating the retinal pigment epithelium and photoreceptors, we conclude that SR is therefore the preferable procedure in most current ocular gene therapy scenarios. This may of course change with the advent of new viral vectors [30] [31] [32] [33] [34] [35] and improvements in intravitreal surgery, 36, 37 which promise to efficiently transduce cells of the outer retina after intravitreal delivery.
While these results were generated using rAAV8, there is reason to believe that the mechanics underlying shedding and biodistribution are also applicable to other AAV serotypes with similar tropism. As most transgene cassettes in classic gene augmentation strategies feature target cell-specific promoters, off-target transduction with nonintegrating vectors such as AAV can still be regarded as fairly safe-especially as the germ line is shown not to be affected. However, in approaches using either ubiquitous promoters or immunogenic bacterial enzymes (e.g., CRISPR-Cas9) to edit genomic DNA with less than 100% specificity, off-target transduction may be more of a concern. 38 FIGURE 9. Summary and proposed model of biodistribution following intravitreal administration of AAV8. Intravitreal injection or retinal tear after subretinal injection leads to (1) persistent presence of vector in the aqueous humor and anterior chamber with (2) access to the venous system through Schlemm's canal. This study demonstrated long-term persistence of (3) vector in the blood and (4) deposition in lymphatic organs. The resulting prolonged and close contact with the immune system (5) might help to explain (6) acute or delayed inflammation observed after gene therapy.
